Guizhou Xinbang Pharmaceutical, the company that sold its products at a loss, is going to Hong Kong Stock Exchange.
The Hong Kong Stock Exchange IPO application wave may be imminent. Since May of this year, 22 companies have submitted IPO applications to the Hong Kong Stock Exchange, while the Shanghai and Shenzhen stock exchanges are still in a state of "0 acceptance" during the same period. As a member of the vast army of IPO applications, Taide Pharmaceutical (Zhejiang) Co., Ltd. (referred to as "Taide Pharmaceutical") is launching a sprint towards the Hong Kong Stock Exchange. The application materials showed that Taide Pharmaceutical mainly provides peptide new chemical molecular entity discovery synthesis (CRO) and peptide chemical production, manufacturing and control (CDMO) services to pharmaceutical companies. In the reporting period, Taide Pharmaceutical has already achieved profits. From 2021 to 2023.
2024 Financial Report | After breaking through 40 billion dollars in revenue, how can Huadong Pharmaceutical face the challenge of “deceleration”
Big dividends
2024 Financial Report | After the dividend ratio is close to 100%, Donga Ejiao still has 8 billion
Extravagant dividends
2024 Financial Report | Profit growth hit its lowest level in 10 years. Is Changchun Gaoxin's growth hormone ceiling here?
The time for the “first strain of growth hormone” to slow down has arrived. On March 20, Changchun Hi-Tech (000661.SZ) released its 2023 financial report, showing that current revenue and net profit to mother were 14.566 billion yuan and 4.532 billion yuan respectively, up 15.35% and 9.47% year-on-year respectively. This net profit growth rate to mother hit a record low since 2014. On March 20, Changchun Hi-Tech closed down 2.57%. Specifically, the current revenue and net revenue of Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”), the core subsidiary responsible for growth hormone under Changchun Hi-Tech
Backed by Huadong Pharmaceutical, Quanxin Biotech's All in the Field of Self-Immunity | Insight Research
Through a hearing on the Hong Kong Stock Exchange, the secondary market also welcomed a major free player.
Evotec's Partner Zhejiang Jingxin Pharmaceutical Secures Approval From Chinese Medical Authority For Evotec's Insomnia Drug, EVT201